We identified a potent antiviral oligonucleotide against the SFTS (Severe fever with thrombocytopenia syndrome) virus jointly with the Japan Institute for Health Security and the National Institute of Infectious Diseases.

In collaboration with Japan Institute for Health Security National Institute of Infectious Diseases, we have conducted basic research for the development of silencing nucleic acid drugs rationally designed based on the SFTS virus genome sequence. Through the second screening process using in vitro SFTS virus infection system, we have identified a series of oligonucleotide sequences that show a potent antiviral effect against SFTS virus-infected cells.

SFTS is mainly transmitted through tick bites carrying the virus. However, recent cases of human-to-human transmission have also been confirmed, in addition to transmission from dogs and cats. As of August 16th this year, 135 cases have been reported in Japan, and over 1,000 people are infected annually in China, with a very high fatality rate of 15-25%. Cases that develop into encephalitis have a particularly poor prognosis. While infections were previously reported mainly in western Japan, this year has seen a nationwide spread, including central and eastern regions, and as far north as Hokkaido.

We are also developing drug delivery systems to transport nucleic acids to the necessary organs, including technologies that target the brain.

For research use of the anti-SFTS nucleic acid or our nucleic acid delivery technology, please contact delivery110@genaheadbio.com. For general inquiries, please reach out to general110@genaheadbio.com.